Accellta

Industrial-Scale Stem Cell Culturing for Research and Medicine

Health Tech & Life Sciences
Active
Mature Haifa, Israel Founded 2012
Last updated 2026-06-18
Total raised
$500K
Last: Grant 2024-01
Stage
Mature
Founded
2012
Headcount
17
HQ
Haifa, Israel
Sector
Health Tech & Life Sciences

About

Accellta specializes in large-scale production of embryonic and induced pluripotent stem cells, progenitors, and differentiated cells. These products are used in cell banking, drug discovery, regenerative medicine, and scientific research.

The company uses 3D carrier-free suspension systems under feeder-free, adherent-free, and xeno-free conditions, optimizing production efficiency and reducing costs while maintaining consistent quality.

Accellta's manufacturing facility adheres to Good Manufacturing Practice (GMP) guidelines, supporting industrial-scale cell banking and clinical batch production. The company’s patent portfolio covers media formulations and pluripotent stem cell culturing techniques, reflecting its focus on advancing cell culture technologies.

Funding history · 3 rounds · $500K total

Q&A

What is Accellta's primary focus?
Accellta specializes in the industrial-scale production of embryonic and induced pluripotent stem cells, progenitors, and differentiated cells for applications in cell banking, drug discovery, regenerative medicine, and scientific research.
How does Accellta differentiate its cell culturing technology?
Accellta utilizes 3D carrier-free suspension systems under feeder-free, adherent-free, and xeno-free conditions to optimize production efficiency and reduce costs while maintaining consistent quality.
When was Accellta founded?
Accellta was founded in November 2012.
What is the current employee count for Accellta?
Accellta has 17 employees, falling within the 11-50 employee bucket.
What was Accellta's most recent funding event?
In January 2024, Accellta received a Grant of $500,000 from the Israel Innovation Authority.
What is Accellta's total amount raised to date?
Accellta has raised a total of $500,000 USD.
Does Accellta hold any patents?
Yes, Accellta holds patents covering media formulations and pluripotent stem cell culturing techniques.
What is the primary sector Accellta operates in?
Accellta's primary sector is Health Tech & Life Sciences.

Sectors & technology

Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
BiologicalsCells
Target customers
Agriculture & FoodProcessed FoodsBeveragesHealthcare & Life SciencesLife SciencesPharmaceuticalsBiotechnologyHealthcareProvidersLaboratoriesIndustrial ManufacturingManufacturing Facilities
Business model
B2B

Highlights

1 PatentsVerified

Tags

foodtechregenerative-medicinebiotechnologymedical-technologiesstem-cellsbioprocesslaboratories3d-technologydrug-discoverypharma-companieshealthcare-providersfood-and-beveragemanufacturing-facilitiesclinics
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)